Iris Acquisition CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Iris Acquisition Corp. stockholders overwhelmingly approved the business combination with Liminatus Pharma at a special meeting held on March 4, 2025.
Iris Acquisition Corp has filed an amendment to its registration statement related to its proposed business combination with Liminatus Pharma.
Iris Acquisition Corp has filed an amendment to its registration statement regarding its proposed business combination with Liminatus Pharma, moving closer to a shareholder vote.
Iris Acquisition Corp. determined that previously issued financial statements for Q2 and Q3 2024 should no longer be relied upon due to an undisclosed related party loan.
Iris Acquisition Corp. has extended the deadline for its business combination with Liminatus Pharma to June 30, 2025, after securing shareholder approval and amending related agreements.
Iris Acquisition Corp reports a $1.12 million loan facilitated by an affiliate of Liminatus Pharma's CEO to enable the acquisition of the former managing member of the company's sponsor.
Iris Acquisition Corp has filed an amendment to its registration statement related to its proposed business combination with Liminatus Pharma.
Iris Acquisition Corp. has significantly reduced the enterprise value of Liminatus Pharma to $175 million and amended its PIPE agreement, lowering the investment to $15 million.
Iris Acquisition Corp will be delisted from the Nasdaq Capital Market, effective September 6, 2024, despite securing an extension to complete a business combination.
Iris Acquisition Corp is facing potential delisting from Nasdaq due to a late filing of its Q2 2024 Form 10-Q, adding to previous non-compliance issues.
Iris Acquisition Corp has cancelled its special stockholder meeting scheduled for August 29th and plans to reschedule it to vote on a business combination agreement.
Iris Acquisition Corp has filed an amendment to its registration statement related to its proposed business combination with Liminatus Pharma, LLC.
Iris Acquisition Corp has filed an amendment to its S-4 registration statement, including a preliminary proxy statement/prospectus, related to its proposed business combination with Liminatus Pharma.
8-K: Iris Acquisition Corp Files Amendment No. 2 for Proposed Business Combination with Liminatus Pharma
Iris Acquisition Corp has filed an amendment to its registration statement regarding its proposed business combination with Liminatus Pharma, including a preliminary proxy statement/prospectus.
Iris Acquisition Corp. has extended the deadline to complete its business combination with Liminatus Pharma to September 3, 2024, and amended its PIPE agreement, reducing the share commitment and terminating a convertible note agreement.
Iris Acquisition Corp has been granted an extension by the Nasdaq Hearings Panel to demonstrate compliance with listing requirements until September 3, 2024.
Iris Acquisition Corp has received a notice from Nasdaq that its failure to maintain the minimum number of publicly held shares is an additional basis for potential delisting.
8-K: Iris Acquisition Corp. Extends Business Combination Deadline with Liminatus Pharma to July 31, 2024
Iris Acquisition Corp. has extended the deadline to complete its business combination with Liminatus Pharma to July 31, 2024, through a third amendment to their agreement.
8-K: Iris Acquisition Corp Extends Business Combination Deadline, Secures Additional Funding and Support
Iris Acquisition Corp has extended its business combination deadline to June 9, 2024, increased its loan facility to $2.5 million, and secured administrative support services.
Iris Acquisition Corp received a delisting notice from Nasdaq for not completing a business combination within the required timeframe and intends to appeal the decision.